课题基金 / 基金详情

CRYO-ROP HEADQUARTERS - PHASE III

CRYO-ROP HEADQUARTERS - PHASE III
CRYO-ROP 总部 - 第三期
批准号:
2710883
负责人:
EARL A PALMER
金额:
$19.02万
依托单位国家:
美国
项目类别:
财政年份:
1990
资助国家:
美国
项目状态:
已结题
起止时间:
1990-06-01 至 1999-08-31

项目摘要

项目成果

EARL A PALMER的其他基金

相似基金

相关文献

中文摘要
翻译
描述(研究者摘要)
英文摘要
DESCRIPTION (Investigator's Abstract) The purpose of the proposed study is to examine the long-term structural and functional effects of cryotherapy as a treatment for severe retinopathy of prematurity (ROP). In January 1986, infants weighing less than 1251 g. at birth were first enrolled in a prospective examinations sequence that led to the participation of 291 such infants in a randomized trial of cryotherapy for a specified threshold severity of ROP. Follow-up to age 12 months indicated that cryotherapy reduced the incidence of unfavorable structural outcome by 45.8 percent and the incidence of unfavorable visual acuity outcome by 37.8 percent. Based on the preliminary data, follow-up to age 12 months during Phase II of the study indicates that cryotherapy reduced the incidence of unfavorable structural outcome by 39.1 percent. As for vision, cryotherapy reduced the incidence of unfavorable resolution acuity outcome by 21.4 percent, and by 19.7 percent when based on measurement of recognition acuity. The diminished outcome difference between the treated eyes and the untreated eyes, particularly for visual acuity, raises sufficient uncertainty that it is deemed vital to continue following this population until the impact of cryotherapy on ocular visual development in these patients through childhood can be firmly established. It is necessary to place this newly popular therapy into clinical perspective. The enrolled children represent a unique group in which a control group of eyes is available for comparison. The present proposal would continue to follow the randomized patients and a relatively small additional subgroup (67) of potentially high risk patients (who nearly qualified for the therapy trial) through age 10 years, to determine whether the reduction in the benefit of cryotherapy suggested by the data between ages 12 and 12 months will continue into mid-childhood. Evaluation of outcome and the effects of cryotherapy will be based on examination findings in the posterior pole of the eye and on assessment of vision. In addition to acuity, vision will be assessed at age 9 years in terms of monocular contrast sensitivity, monocular color vision, and stereopsis; and at age 10 years, through measurement of the extent of the visual field by Goldmann perimetry.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CRYO-ROP HEADQUARTERS--PHASE IV
PHASE II CRYOTHERAPY FOR RETINOPATHY OF PREMATURITY
PHASE II CRYOTHERAPY FOR RETINOPATHY OF PREMATURITY
CRYO ROP HEADQUARTERS--PHASE IV
海外基金